Actualités dans la prise en charge des cancers thyroïdiens de souche vésiculaire
Tóm tắt
Từ khóa
Tài liệu tham khảo
Sciuto, 2009, Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution, Ann Oncol, 20, 1728, 10.1093/annonc/mdp050
Morris, 2013, The increasing incidence of thyroid cancer: the influence of access to care, Thyroid, 23, 885, 10.1089/thy.2013.0045
Cooper, 2009, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 19, 1167, 10.1089/thy.2009.0110
Castagna, 2011, Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients, Eur J Endocrinol, 165, 441, 10.1530/EJE-11-0466
Vaisman, 2012, Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy, Clin Endocrinol (Oxf), 77, 132, 10.1111/j.1365-2265.2012.04342.x
Pitoia, 2013, Outcomes of patients with differentiated thyroid cancer riskstratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems, Thyroid, 23, 1401, 10.1089/thy.2013.0011
Randolph, 2012, The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension, Thyroid., 22, 1144, 10.1089/thy.2012.0043
2014 American Thyroid Association (ATA) Guidelines on Thyroid nodules and Differentiated Thyroid Cancer-Highlights, Consensus, and Controversies, ICE/ENDO 2014 Preconference Events, Chicago.
Hsiao, 2014, Molecular approaches to thyroid cancer diagnosis, Endocr Relat Cancer, 21, T301
Nikiforov, Yuri E. New mutations and gene rearrangements in papillary thyroid cancer. ICE/ENDO 2014 Chicago.
Durand, 2009, Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features, Endocr Relat Cancer, 16, 467, 10.1677/ERC-08-0081
Kimura, 2003, High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, Cancer Res, 63, 1454
Soares, 2003, BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC, Oncogene, 22, 4578, 10.1038/sj.onc.1206706
Ciampi, 2005, Alterations of the BRAF gene in thyroid tumors, Endocr Pathol, 16, 163, 10.1385/EP:16:3:163
Jung, 2014, The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations, J Clin Endocrinol Metab, 99, E276, 10.1210/jc.2013-2503
Nikiforova, 2003, BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas, J Clin Endocrinol Metab, 88, 5399, 10.1210/jc.2003-030838
Elisei, 2008, BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study, J Clin Endocrinol Metab, 93, 3943, 10.1210/jc.2008-0607
Xing, 2005, BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer, J Clin Endocrinol Metab, 90, 6373, 10.1210/jc.2005-0987
Tufano, 2012, BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis, Medicine (Baltimore), 91, 274, 10.1097/MD.0b013e31826a9c71
Xing, 2013, Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer, JAMA, 309, 1493, 10.1001/jama.2013.3190
Ricarte-Filho, 2009, Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1, Cancer Res, 69, 4885, 10.1158/0008-5472.CAN-09-0727
Fagin, 1993, High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas, J Clin Invest, 91, 179, 10.1172/JCI116168
Nikiforova, 2013, Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer, J Clin Endocrinol Metab, 98, E1852, 10.1210/jc.2013-2292
Pacini, 2014
Melo, 2014, TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas, J Clin Endocrinol Metab, 99, E754, 10.1210/jc.2013-3734
Xing, 2014, BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence, J Clin Oncol, 32, 2718, 10.1200/JCO.2014.55.5094
Rubino, 2003, Second primary malignancies in thyroid cancer patients, Br J Cancer, 89, 1638, 10.1038/sj.bjc.6601319
Mandel, 2003, Radioactive iodine and the salivary glands, Thyroid, 13, 265, 10.1089/105072503321582060
Kloos, 2002, Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma, J Clin Endocrinol Metab, 87, 5817, 10.1210/jc.2002-020210
Buffet C. Meet the Professor: radioiodine therapy in thyroid cancer: when and how much to use? ICE/ENDO 2014, Chicago.
Leboulleux, 2014, Thyroid cancer and administration of radioactive iodine, Médecine Nucléaire, 38, 172, 10.1016/j.mednuc.2014.03.132
Borson-Chazot, 2008, Guidelines for the management of differentiated thyroid carcinomas of vesicular origin, Ann Endocrinol (Paris), 69, 472, 10.1016/j.ando.2008.10.002
Pacini, 2006, European Thyroid Cancer Taskforce, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium, Eur J Endocrinol, 154, 787, 10.1530/eje.1.02158
Schvartz, 2012, Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients, J Clin Endocrinol Metab, 97, 1526, 10.1210/jc.2011-2512
Jonklaas, 2006, Outcomes of patients with differentiated thyroid carcinoma following initial therapy, Thyroid, 16, 1229, 10.1089/thy.2006.16.1229
Hay, 2002, Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients, World J Surg, 26, 879, 10.1007/s00268-002-6612-1
Sawka, 2004, Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer, J Clin Endocrinol Metab, 89, 3668, 10.1210/jc.2003-031167
Brierley, 2005, Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years, Clin Endocrinol (Oxf), 63, 418, 10.1111/j.1365-2265.2005.02358.x
Cheng, 2013, Lowor high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis, J Clin Endocrinol Metab, 98, 1353, 10.1210/jc.2012-3682
Schlumberger, 2012, Strategies of radioiodine ablation in patients with low-risk thyroid cancer, N Engl J Med, 366, 1663, 10.1056/NEJMoa1108586
Mallick, 2012, Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer, N Engl J Med, 366, 1674, 10.1056/NEJMoa1109589
Momesso, 2014, Update on differentiated thyroid cancer staging, Endocrinol Metab Clin North Am, 43, 401, 10.1016/j.ecl.2014.02.010
Heemstra, 2006, The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma, Thyroid, 16, 583, 10.1089/thy.2006.16.583
Tournis S, Antoniou JD, Liakou CG, Christodoulou J, Papakitsou E, Galanos A, et al. Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clin Endocrinol (Oxf) 2014 (in press).
Bauer, 2001, Risk for fracture in women with low serum levels of thyroid-stimulating hormone, Ann Intern Med, 134, 561, 10.7326/0003-4819-134-7-200104030-00009
Pearce, 2013, Global iodine nutrition: Where do we stand in 2013?, Thyroid, 23, 523, 10.1089/thy.2013.0128
Garin, 2014, Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study, J Clin Endocrinol Metab, 99, 2657, 10.1210/jc.2014-1051
Flynn, 2010, Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy, J Clin Endocrinol Metab, 95, 186, 10.1210/jc.2009-1625
McLeod, 2013, Controversies in primary treatment of low-risk papillary thyroid cancer, Lancet, 381, 1046, 10.1016/S0140-6736(12)62205-3
Biondi, 2010, Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer, Thyroid, 20, 135, 10.1089/thy.2009.0311
Pacini, 2012, Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 23, vii110, 10.1093/annonc/mds230
Durante, 2006, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy, J Clin Endocrinol Metab, 91, 2892, 10.1210/jc.2005-2838
Schlumberger, 2014, Definition and management of radioactive iodine-refractory differentiated thyroid cancer, Lancet Diabetes Endocrinol, 2, 356, 10.1016/S2213-8587(13)70215-8
Xing, 2013, Progress in molecular- based management of differentiated thyroid cancer, Lancet, 381, 1058, 10.1016/S0140-6736(13)60109-9
Sherman, 2010, Cytotoxic chemotherapy for differentiated thyroid carcinoma, Clin Oncol (R Coll Radiol), 22, 464, 10.1016/j.clon.2010.03.014
Spitzweg C, Bible KC, Hofbauer LC, Morris JC. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol 2014 (in press).
Felsher, 1999, Reversible tumorigenesis by MYC in hematopoietic lineages, Mol Cell, 4, 199, 10.1016/S1097-2765(00)80367-6
Fisher, 2001, Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes, Genes Dev, 15, 3249, 10.1101/gad.947701
D’Cruz, 2001, c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations, Nat Med., 7, 235, 10.1038/84691
Leboulleux, 2012, Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, doubleblind, phase 2 trial, Lancet Oncol, 13, 897, 10.1016/S1470-2045(12)70335-2
Brose, 2014, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet, 384, 319, 10.1016/S0140-6736(14)60421-9
Schlumberger, 2013, Phase III randomized, double-blinded, placebo- controlled trial of sorafenib in locally advanced or metastatic patients with RAI-refractory differntiated thyroid cancer – exploratory anallyses of patient-reported outcomes, ATA, Annual Meeting Oral 100 – Thyroid Cancer Clinical
Sivendran, 2012, Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis, Cancer Treat Rev, 38, 919, 10.1016/j.ctrv.2012.05.001
Fröhlich, 2014, The current role of targeted therapies to induce radioiodine uptake in thyroid cancer, Cancer Treat Rev, 40, 665, 10.1016/j.ctrv.2014.01.002
Coelho, 2004, Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma, J Endocrinol Invest, 27, 334, 10.1007/BF03351058
Handkiewicz-Junak, 2009, 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin- aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study, Thyroid Res, 2, 8, 10.1186/1756-6614-2-8
Simon, 2002, Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study, Eur J Nucl Med Mol Imaging, 29, 775, 10.1007/s00259-001-0737-6
Liu, 2006, Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies, Clin Endocrinol (Oxf), 64, 617, 10.1111/j.1365-2265.2006.02515.x
Durante, 2007, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism, J Clin Endocrinol Metab, 92, 2840, 10.1210/jc.2006-2707
Chakravarty, 2011, Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation, J Clin Invest, 121, 4700, 10.1172/JCI46382
Ho, 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer, N Engl J Med, 368, 623, 10.1056/NEJMoa1209288
Fagin JA. Clinical investigator award lecture: thyroid cancer: from genetics to biology to new treatment strategies. ICE /Endo 2014, Chicago.
Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056/NEJMoa1002011
Brose, 2013, Vemurafenib in patients with rai refractory, progressive, brafv600e-mutated papillary thyroid cancer, ESMO